[ 메디채널 김갑성 기자 ] - Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral discussion - On track to report topline data from Phase IIa clinical study of ASC30 oral tablet in participants with obesity or overweight in the fourth quarter of 2025 HONG KONG, Sept. 2, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that data from its 28-day multiple ascending dose study of its oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 (NCT06680440) will be presented in a short oral discussion at the 61st European Associ
[ 메디채널 황정호 기자 ] A special meeting of stockholders will be held on Wednesday, September 10, 2025, at 9:00 AM local time or 9:00 PM EDT on Tuesday, September 9, 2025 WUHAN, China, Sept. 2, 2025 -- China Automotive Systems, Inc. (Nasdaq: CAAS) ("CAAS" or the "Company"), a leading power steering components and systems supplier in China, today announced that a Special Meeting of Stockholders of China Automotive Systems, Inc. will be held on September 10, 2025 (Wednesday) at 9:00 am at the Second Floor Meeting Room, D8 Henglong Building, Optics Valley Software Park, No.
SHANGHAI, Sept. 2, 2025 -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine the oral potential of small molecules with the structural advantages of biologics—making them ideally suited to address traditionally "undruggable" protein–protein interactions and complex receptors, while opening new avenues for oral drug discovery. With global investment in peptide pipelines steadily
The study also found that youths in ASEAN fall behind in financial readiness, with Singapore's Gen Zs most at risk SINGAPORE, Sept. 2, 2025 -- In the sixth edition of the ASEAN Consumer Sentiment Study (ACSS)[1], the region's leading consumer confidence barometer, UOB launched ASEAN's first UOB ASEAN Consumer Sentiment Index (the Index). The Index was based on six key indicators from ACSS, covering consumers' confidence level of their countries' current and future economic conditions and their personal finances. The 2025 regional Index was 54, where a level above 50 reflected c
HONG KONG, Sept. 2, 2025 -- ATFX, a globally trusted online brokerage, proudly served as Platinum Sponsor at Money Expo India 2025, held on August 23–24, 2025, at the Jio World Convention Centre in Mumbai. Through the Platinum Sponsorship, ATFX strengthened its presence in one of Asia's fastest-growing financial markets, reinforcing its focus on innovation and strengthening connections with traders and industry leaders across the region. Positioned as India's premier trading and fintech expo, Money Expo India 2025 brought together banks, brokers, fintech innovators, and thousands of re
[ 메디채널 김갑성 기자 ] Capital injection to accelerate M&A, AI-led operations, and expansion across Southeast Asia and the Middle East. SINGAPORE, Sept. 2, 2025 -- Nuffield Holdings is pleased to announce the appointment of Mr Liu Song and Ms Zhang Na as new shareholders, marking a pivotal moment in the Group's regional growth strategy. This investment brings in both capital and strategic insight, enabling Nuffield to accelerate mergers and acquisitions, scale operations, and enhance its leadership in Southeast Asia's healthcare sector. Experienced and Visionary Partners M
TAIPEI, Sept. 2, 2025 -- The 2025 Kaohsiung Food Show will return to the Kaohsiung Exhibition Center from October 23–26, 2025. Running concurrently with the Kaohsiung International Hotel, Restaurant, Baking and Catering Show (Kaohsiung HORECA), the event will transform Southern Taiwan into a dynamic hub for the food and hospitality industries in the Asia-Pacific region. This year's exhibition brings together 330 exhibitors across 580 booths, attracting an expected 20,000 visitors. Covering the entire food supply chain, the show features everything from agricultural, fishery and
HONG KONG, Sept. 2, 2025 -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study evaluating ivonescimab, in combination with standard therapy, against durvalumab (PD-L1) combination therapy, for the first-line treatment of advanced biliary tract cancer (BTC) (AK112-309/HARMONi-GI1). This Phase III trial is being conducted in China. Ivonescimab has previously shown significant positive results in the randomized, double-blind, controlled Phase III study (HARMONi-2), where it was compared he
[ 메디채널 황정호 기자 ] A multi-stakeholder partnership between Save the Children, the Italian Cooperation, and Ferrero to improve children's living conditions, enhance their well-being, and combat child labour LUXEMBOURG, Sept. 2, 2025 -- An innovative initiative bringing together institutions, private sector, and civil society to protect children and adolescents living in cocoa-farming communities in Côte d'Ivoire. This is the core of a new multi-stakeholder partnership between the Italian Cooperation, Save the Children, and Ferrero, with activities set to take place in the Haut Sass
SHIHEZI, China, Sept. 2, 2025 -- On August 29, 2025, the second Low-Altitude Industry Innovation and Development Conference was successfully held in Shihezi City, Xinjiang, China. During the conference, China's Ursa Aeronautical Technology Co., Ltd. ("Ursa") reached a procurement agreement with Indonesia's PT Unmanned Airtransport Indonesia for 20 sets of HY100 Unmanned Aircraft Systems (UASs). Additionally, the company signed a procurement agreement with the government of the Republic of Equatorial Guinea for 10 sets of the systems, and established strategic service partnerships wi